Toward minimal conditioning protocols for allogeneic chimerism in tolerance resistant recipients

Chimerism

Volumn 4, Issue 1, 2013, Pages 23-25

  Al Adra, David P ^a   Anderson, Colin C ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Chimerism; Cyclophosphamide; Hematopoietic stem cell; Split tolerance; Tolerance; Transplantation

Indexed keywords

BUSULFAN; CD4 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM1 ANTIBODY; OKT 8; RAPAMYCIN; CD40 LIGAND;

ALLOGENEIC MIXED CHIMERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW TRANSPLANTATION; DONOR SPECIFIC TRANSFUSION; GRAFT REJECTION; IMMUNOCOMPETENCE; IMMUNOLOGICAL PARAMETERS; IMMUNOLOGICAL TOLERANCE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; NONMYELOABLATIVE CONDITIONING; NONOBESE DIABETIC MOUSE; SINGLE DRUG DOSE; T CELL DEPLETION; TRANSFUSION; ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL; CYTOLOGY; GENETICS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MALE; PANCREAS ISLET TRANSPLANTATION; T LYMPHOCYTE;

ALLOGRAFTS; ANIMALS; CD40 LIGAND; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED NOD; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872960689     PISSN: 19381956     EISSN: 19381964     Source Type: Journal    
DOI: 10.4161/chim.23350     Document Type: Article

References (22)

1. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358:362-8; PMID:18216356; http://dx.doi.org/10.1056/ NEJMoa074191.
2. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, et al. HLAmismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358:353-61; PMID:18216355; http://dx.doi. org/10.1056/NEJMoa071074.
3. Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4:24ra28; PMID:22399264; http://dx.doi. org/10.1126/scitranslmed.3003509.
4. Al-Adra DP, Pawlick R, Shapiro AM, Anderson CC. Targeting cells causing split tolerance allows fully allogeneic islet survival with minimal conditioning in NOD mixed chimeras. Am J Transplant 2012; 12:3235-45; PMID:22974315; http://dx.doi. org/10.1111/j.1600-6143.2012.04260.x.
5. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13:391-7; PMID:15230298; http://dx.doi.org/10.1191/0961203304lu1032oa.
6. Savage KJ. Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2011; 2011:515-24; PMID:22160083; http://dx.doi. org/10.1182/asheducation-2011.1.515.
7. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M, Ilowite N, et al.; Carra SLE Subcommittee. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64:375-83; PMID:22162255; http://dx.doi.org/10.1002/acr.21558.
8. Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115:3224-30; PMID:20124511; http://dx.doi.org/10.1182/blood-2009-11-251595.
9. Tomita Y, Yoshikawa M, Zhang QW, Shimizu I, Okano S, Iwai T, et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J Immunol 2000; 165:34-41; PMID:10861032.
10. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001; 98:3456-64; PMID:11719388; http://dx.doi.org/10.1182/blood.V98.12.3456.
11. Onzuka T, Tomita Y, Shimizu I, Okano S, Yamada H, Yoshikai Y, et al. Effects of lipopolysaccharide on the induction of mixed chimerism in cyclophosphamide-induced tolerance. Scand J Immunol 2009; 70:423-30; PMID:19874546; http://dx.doi. org/10.1111/j.1365-3083.2009.02314.x.
12. Iwai T, Tomita Y, Zhang QW, Shimizu I, Nomoto K, Yasui H. Requirement of a higher degree of chimerism for skin allograft tolerance in cyclophosphamide-induced tolerance. Transpl Int 2005; 17:795-803; PMID:15856178; http://dx.doi.org/10.1007/ s00147-003-0675-2.
13. Xu H, Chilton PM, Huang Y, Schanie CL, Yan J, Ildstad ST. Addition of cyclophosphamide to T-cell depletion-based nonmyeloablative conditioning allows donor T-cell engraftment and clonal deletion of alloreactive host T-cells after bone marrow transplantation. Transplantation 2007; 83:954-63; PMID:17460568; http://dx.doi.org/10.1097/01. tp.0000258679.18684.b0.
14. Maeda T, Eto M, Nishimura Y, Nomoto K, Kong YY, Nomoto K. Direct evidence for clonal destruction of allo-reactive T cells in the mice treated with cyclophosphamide after allo-priming. Immunology 1993; 78:113-21; PMID:8436396.
15. Harada M, Makino S. Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide. Diabetologia 1984; 27:604-6; PMID:6530055; http://dx.doi.org/10.1007/ BF00276978.
16. Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006; 177:6603-12; PMID:17082572.
17. Chan WF, Razavy H, Luo B, Shapiro AM, Anderson CC. Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras. J Immunol 2008; 180:5177-86; PMID:18390699.
18. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-8; PMID:15746082; http://dx.doi.org/10.1182/blood-2004-10-3932.
19. Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol 2007; 17:153-61; PMID:17331841; http://dx.doi.org/10.1016/j.trim.2007.01.002.
20. Pearson T, Markees TG, Serreze DV, Pierce MA, Marron MP, Wicker LS, et al. Genetic disassociation of autoimmunity and resistance to costimulation blockade-induced transplantation tolerance in nonobese diabetic mice. J Immunol 2003; 171:185-95; PMID:12816997.
21. Pearson T, Markees TG, Serreze DV, Pierce MA, Wicker LS, Peterson LB, et al. Islet cell autoimmunity and transplantation tolerance: two distinct mechanisms? Ann N Y Acad Sci 2003; 1005:148-56; PMID:14679049; http://dx.doi.org/10.1196/ annals.1288.016.
22. Pearson T, Markees TG, Wicker LS, Serreze DV, Peterson LB, Mordes JP, et al. NOD congenic mice genetically protected from autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes 2003; 52:321-6; PMID:12540603; http://dx.doi.org/10.2337/diabetes.52.2.321.